SCHEMBL2755774

SCHEMBL2755774

CC(C)Oc1ccc2c(c1)CCc1c-2c2c(c3c1[nH]c1ccc(O)cc13)CNC2=O

nearest known ligand 0.79

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAP3K9 P80192 4/20 0.79
▸ MAP3K11 Q16584 4/20 0.79
▸ ROCK2 O75116 6/20 0.57
▸ NTRK1 P04629 1/20 0.55
▸ FYN P06241 1/20 0.55
▸ FLT4 P35916 1/20 0.55
▸ MAP3K10 Q02779 1/20 0.55
▸ KDR P35968 7/20 0.53
▸ PRKCA P17252 2/20 0.51
▸ MAP3K5 Q99683 2/20 0.51
▸ IKBKB O14920 1/20 0.51
▸ PIM1 P11309 1/20 0.51
▸ PRKCQ Q04759 1/20 0.51
▸ PRKCD Q05655 1/20 0.51
▸ ROCK1 Q13464 1/20 0.51
▸ TEK Q02763 5/20 0.48
▸ PARP1 P09874 2/20 0.46
▸ WEE1 P30291 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3265885 0.90 MAP3K9 (0.79) MAP3K9MAP3K11ROCK2NTRK1FYN
SCHEMBL2755760 0.85 MAP3K9 (0.69) MAP3K9MAP3K11NTRK1FYNFLT4
SCHEMBL3264738 0.84 MAP3K9 (0.68) MAP3K9MAP3K11ROCK2NTRK1FYN
SCHEMBL14589768 0.83 MAP3K9 (0.67) MAP3K9MAP3K11ROCK2NTRK1FYN
SCHEMBL2755761 0.82 MAP3K9 (0.68) MAP3K9MAP3K11NTRK1FYNFLT4
SCHEMBL3264416 0.80 MAP3K9 (0.77) MAP3K9MAP3K11ROCK2NTRK1MAP3K10
SCHEMBL12250076 0.78 MAP3K9 (0.70) MAP3K9MAP3K11ROCK2NTRK1FYN
SCHEMBL2755778 0.78 MAP3K9 (1.00) MAP3K9MAP3K11ROCK2NTRK1FYN
SCHEMBL2755776 0.76 MAP3K9 (0.67) MAP3K9MAP3K11ROCK2NTRK1FYN
SCHEMBL2755775 0.76 MAP3K9 (0.64) MAP3K9MAP3K11ROCK2NTRK1FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383813-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2013-02-26 — — US disclosed
US-8383813-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2013-02-26 — — US disclosed
US-20120004253-A1 Novel Fused Pyrrolocarbazoles CEPHALON, INC. (US) 2012-01-05 — — US disclosed
US-20120004253-A1 Novel Fused Pyrrolocarbazoles CEPHALON, INC. (US) 2012-01-05 — — US disclosed
US-8084472-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2011-12-27 — — US disclosed
US-8084472-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2011-12-27 — — US disclosed
US-8044064-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2011-10-25 — — US disclosed
US-8044064-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2011-10-25 — — US disclosed
EP-1704148-B1 NOVEL FUSED PYRROLOCARBAZOLES CEPHALON INC (US) 2011-03-02 — — EP disclosed
US-20100152196-A1 Novel Fused Pyrrolocarbazoles CEPHALON, INC. (US) 2010-06-17 — — US disclosed
US-20090186888-A1 NOVEL FUSED PYRROLOCARBAZOLES CEPHALON, INC. (US) 2009-07-23 — — US disclosed
US-7514440-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2009-04-07 — — US disclosed
US-7514440-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2009-04-07 — — US disclosed
US-20070203135-A1 Novel Fused Pyrrolocarbazoles CEPHALON, INC. (US) 2007-08-30 — — US disclosed
US-20070203135-A1 Novel Fused Pyrrolocarbazoles CEPHALON, INC. (US) 2007-08-30 — — US disclosed
US-7241779-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2007-07-10 — — US disclosed
US-7241779-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2007-07-10 — — US disclosed
US-7169802-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2007-01-30 — — US disclosed
US-7169802-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2007-01-30 — — US disclosed
WO-2005063763-A1 NOVEL FUSED PYRROLOCARBAZOLES CEPHALON, INC. (US) 2005-07-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152196-A1 Novel Fused Pyrrolocarbazoles PC, PYCR1, CYP11B2 MAP3K9 3651/4885MAP3K11 3535/4885ROCK2 1453/4885
US-20120004253-A1 Novel Fused Pyrrolocarbazoles PC, PYCR1, CYP11B2 MAP3K9 3651/4885MAP3K11 3535/4885ROCK2 1453/4885
US-20090186888-A1 NOVEL FUSED PYRROLOCARBAZOLES PC, PYCR1, CYP11B2 MAP3K9 3651/4885MAP3K11 3535/4885ROCK2 1453/4885
US-20070203135-A1 Novel Fused Pyrrolocarbazoles PC, PYCR1, CYP11B2 MAP3K9 3651/4885MAP3K11 3535/4885ROCK2 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback